Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.44 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14331191 | 0.88 | EGLN1 (0.44) | EGLN1GRIN2BLATS1FYNEGLN3 | |
| SCHEMBL3485355 | 0.88 | GRIN2B (0.48) | GRIN2B | |
| SCHEMBL1921290 | 0.87 | VEGFA (0.49) | EGLN1GRIN2BLATS1GRM5FYN | |
| SCHEMBL3484981 | 0.86 | EGLN1 (0.47) | EGLN1GRIN2BGRM5CHEK2FYN | |
| SCHEMBL3484354 | 0.85 | EGLN1 (0.46) | EGLN1GRIN2BGRM5CHEK2FYN | |
| SCHEMBL3484817 | 0.82 | EGLN1 (0.57) | EGLN1GRIN2BVEGFAFLT1EGLN3 | |
| SCHEMBL3485538 | 0.78 | ALOX5 (0.44) | LATS1CHEK2HDAC3HDAC1HDAC2 | |
| SCHEMBL3485009 | 0.78 | GRIN2B (0.53) | EGLN1GRIN2BGRM5GSK3AGSK3B | |
| SCHEMBL3484739 | 0.77 | EGLN1 (0.46) | EGLN1GRIN2BGRM5CHEK2FYN | |
| SCHEMBL3485426 | 0.74 | PARP1 (0.50) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885GRIN2B 4440/4885LATS1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.